Targeted overexpression of luteinizing hormone in tran polycystic ovaries, and ovarian tumors.

Proceedings of the National Academy of Sciences of the Unite 92, 1322-1326

DOI: 10.1073/pnas.92.5.1322

Citation Report

#	Article	IF	CITATIONS
1	Disruption of the mouse oestrogen receptor gene: resulting phenotypes and experimental findings. Biochemical Society Transactions, 1995, 23, 929-935.	1.6	58
2	Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice Genes and Development, 1995, 9, 2007-2019.	2.7	236
3	OVARIAN SURFACE EPITHELIUM, OVULATION AND CARCINOGENESIS. Biological Reviews, 1996, 71, 529-543.	4.7	56
4	The inhibin/activin family and ovarian cancer. Trends in Endocrinology and Metabolism, 1996, 7, 197-202.	3.1	13
5	Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice Endocrinology, 1996, 137, 4210-4216.	1.4	103
6	Response to challenge with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptora clinical research center study Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3802-3806.	1.8	53
7	Elevated Luteinizing Hormone in Prepubertal Transgenic Mice Causes Hyperandrogenemia, Precocious Puberty, and Substantial Ovarian Pathology ¹ . Endocrinology, 1997, 138, 3540-3547.	1.4	99
8	Suppression of Gonadotropins Inhibits Gonadal Tumorigenesis in Mice Transgenic for the Mouse Inhibin α-Subunit Promoter/Simian Virus 40 T-Antigen Fusion Gene ¹ . Endocrinology, 1997, 138, 3521-3531.	1.4	46
9	Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*. Endocrine Reviews, 1997, 18, 774-800.	8.9	1,915
10	An essential role for C/EBPβ in female reproduction. Genes and Development, 1997, 11, 2153-2162.	2.7	360
11	Chronically Elevated Luteinizing Hormone Depletes Primordial Follicles in the Mouse Ovary1. Biology of Reproduction, 1997, 57, 1233-1237.	1.2	123
12	Biological impact of a disrupted estrogen receptor gene on estrogen-related cancer. Endocrine-Related Cancer, 1997, 4, 387-406.	1.6	2
13	Control of Differentiation, Transformation, and Apoptosis in Granulosa Cells by Oncogenes, Oncoviruses, and Tumor Suppressor Genes*. Endocrine Reviews, 1997, 18, 435-461.	8.9	106
14	Loss of Heterozygosity at the α-Inhibin Locus on Chromosome 2q Is Not a Feature of Human Granulosa Cell Tumors. Gynecologic Oncology, 1997, 65, 387-390.	0.6	38
15	Developmental and Physiological Effects of Estrogen Receptor Gene Disruption in Mice. Trends in Endocrinology and Metabolism, 1997, 8, 137-145.	3.1	38
16	Exploring the role of sex steroids through studies of receptor deficient mice. Journal of Molecular Medicine, 1998, 76, 497-511.	1.7	86
17	Transgenic mouse models for gonadal tumorigenesis. Molecular and Cellular Endocrinology, 1998, 145, 167-174.	1.6	30
18	POLYCYSTIC OVARY SYNDROME. Endocrinology and Metabolism Clinics of North America, 1998, 27, 877-902.	1.2	69

#	Article	IF	CITATIONS
19	Transient Induction of Polycystic Ovary-Like Syndrome in Immature Hypothyroid Rats. Experimental Biology and Medicine, 1998, 219, 77-84.	1.1	11
20	Molecular Genetic, Biochemical, and Clinical Implications of Gonadotropin Receptor Mutations. Molecular Genetics and Metabolism, 1998, 63, 75-84.	0.5	39
21	Direct Luteinizing Hormone Action Triggers Adrenocortical Tumorigenesis in Castrated Mice Transgenic for The Murine Inhibinα -Subunit Promoter/Simian Virus 40 T-Antigen Fusion Gene. Molecular Endocrinology, 1998, 12, 801-809.	3.7	61
22	Mutations of the G protein-coupled receptors of the hypothalamo-pituitary-gonadal axis. Where do we stand?. European Journal of Endocrinology, 1998, 139, 145-147.	1.9	10
23	Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction, 1999, 14, 2681-2686.	0.4	211
24	Targeted Disruption of the Estrogen Receptor-α Gene in Female Mice: Characterization of Ovarian Responses and Phenotype in the Adult*. Endocrinology, 1999, 140, 2733-2744.	1.4	201
25	Transgenic Mice with Chronically Elevated Luteinizing Hormone Are Infertile Due to Anovulation, Defects in Uterine Receptivity, and Midgestation Pregnancy Failure1. Endocrinology, 1999, 140, 2592-2601.	1.4	38
26	Transgenic Models to Study Gonadotropin Function: The Role of Follicle-Stimulating Hormone in Gonadal Growth and Tumorigenesis. Molecular Endocrinology, 1999, 13, 851-865.	3.7	169
27	Chronic Hypersecretion of Luteinizing Hormone in Transgenic Mice Selectively Alters Responsiveness of the α-Subunit Gene to Gonadotropin-Releasing Hormone and Estrogens. Molecular Endocrinology, 1999, 13, 1449-1459.	3.7	10
28	Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?. Endocrine Reviews, 1999, 20, 358-417.	8.9	1,759
29	Association of molecular variants of luteinizing hormone with menstrual disorders. Clinical Endocrinology, 1999, 51, 243-246.	1.2	40
30	Constitutively Active Mutations of G Protein-Coupled Receptors. Archives of Medical Research, 1999, 30, 501-509.	1.5	17
31	Human chorionic gonadotropin promotes tumorigenesis of choriocarcinoma JAr cells. Placenta, 1999, 20, 147-159.	0.7	12
32	Heterotrimeric Gi/o Proteins Control Cyclic AMP Oscillations and Cytoskeletal Structure Assembly in Primary Human Granulosa-Lutein Cells. Cellular Signalling, 1999, 11, 415-433.	1.7	29
33	Targeted ablation of gonadotrophs in transgenic mice affects embryonic development of lactotrophs. Molecular and Cellular Endocrinology, 1999, 150, 129-139.	1.6	32
34	The role of estrogen in folliculogenesis. Molecular and Cellular Endocrinology, 1999, 151, 57-64.	1.6	141
35	Prevention of the Polycystic Ovarian Phenotype and Characterization of Ovulatory Capacity in the Estrogen Receptor-α Knockout Mouse. Endocrinology, 1999, 140, 5855-5865.	1.4	110
36	Proteolytic and Cellular Death Mechanisms in Ovulatory Ovarian Rupture. NeuroSignals, 2000, 9, 102-114.	0.5	35

#	Article	IF	CITATIONS
37	The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice11A preliminary report of this study was presented at the 54th Annual Meeting of the American Society for Reproductive Medicine, October 3–9, 1998, San Francisco, California Reproductive Toxicology, 2000, 14, 37-44.	1.3	17
38	Transgenics. The Obstetrician and Gynaecologist, 2000, 2, 45-46.	0.2	Ο
39	Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses. EMBO Journal, 2000, 19, 1312-1326.	3.5	311
40	Luteinizing hormone receptor mutations in disorders of sexual development and cancer. Frontiers in Bioscience - Landmark, 2000, 5, d343.	3.0	42
42	The Effect of a Null Mutation in the Follicle-Stimulating Hormone Receptor Gene on Mouse Reproduction ¹ . Endocrinology, 2000, 141, 1795-1803.	1.4	386
43	An Age-Related Ovarian Phenotype in Mice with Targeted Disruption of the Cyp 19 (Aromatase) Gene*. Endocrinology, 2000, 141, 2614-2623.	1.4	203
44	Induction of Mammary Gland Development in Estrogen Receptor-α Knockout Mice. Endocrinology, 2000, 141, 2982-2994.	1.4	189
45	Luteinizing Hormone Receptor Mutations in Disorders of Sexual Development and Cancer. Fetal and Pediatric Pathology, 2000, 19, 21-40.	0.3	8
46	Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 383-387.	3.3	84
47	Gonadotropin Induction of Ovulation and Corpus Luteum Formation in Young Estrogen Receptor- $\hat{l}\pm$ Knockout Mice1. Biology of Reproduction, 2000, 62, 599-605.	1.2	32
48	Receptor null mice reveal contrasting roles for estrogen receptor α and β in reproductive tissues. Journal of Steroid Biochemistry and Molecular Biology, 2000, 74, 287-296.	1.2	140
49	Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function. Endocrine Reviews, 2000, 21, 551-583.	8.9	649
50	The ovarian phenotype of the aromatase knockout (ArKO) mouse. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 181-185.	1.2	119
51	Normal Prenatal but Arrested Postnatal Sexual Development of Luteinizing Hormone Receptor Knockout (LuRKO) Mice. Molecular Endocrinology, 2001, 15, 172-183.	3.7	476
52	Ovarian expression of human insulin-like growth factor-l in transgenic mice results in cyst formation. Molecular Reproduction and Development, 2001, 59, 178-185.	1.0	11
53	Manipulating the <i>In Vivo</i> mRNA Expression Profile of FSHβ to Resemble that of LHβ Does Not Promote a Concomitant Increase in Intracellular Storage of Follicleâ€Stimulating Hormone. Journal of Neuroendocrinology, 2001, 13, 50-62.	1.2	0
54	Identification of Twelve O-Glycosylation Sites in Equine Chorionic Gonadotropin β and Equine Luteinizing Hormone β by Solid-Phase Edman Degradation1. Biology of Reproduction, 2001, 64, 136-147.	1.2	40
55	Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility. Human Molecular Genetics, 2001, 10, 1141-1153.	1.4	102

#	Article	IF	CITATIONS
56	Ovarian Pathology and High Incidence of Sex Cord Tumors in Follitropin Receptor Knockout (FORKO) Mice. Endocrinology, 2001, 142, 3673-3684.	1.4	75
57	Gonadal Pathologies in Transgenic Mice Expressing the Rat Inhibinα -Subunit. Endocrinology, 2001, 142, 5005-5014.	1.4	93
58	Ovarian Tumorigenesis in Mice Transgenic for Murine Inhibin α Subunit Promoter-Driven Simian Virus 40 T-Antigen: Ontogeny, Functional Characteristics, and Endocrine Effects1. Biology of Reproduction, 2001, 64, 1122-1130.	1.2	18
59	Perspective: Male Reproduction. Endocrinology, 2001, 142, 2178-2183.	1.4	16
60	Are Estrogens of Import to Primate/Human Ovarian Folliculogenesis?*. Endocrine Reviews, 2001, 22, 389-424.	8.9	153
61	Activins and Inhibins in Endocrine and Other Tumors. Endocrine Reviews, 2001, 22, 836-858.	8.9	170
62	Lack of association of the common immunologically anomalous LH with endometriosis. Human Reproduction, 2002, 17, 1532-1534.	0.4	7
63	Transgenic Mice Harboring Murine Luteinizing Hormone Receptor Promoter/β-Galactosidase Fusion Genes: Different Structural and Hormonal Requirements of Expression in the Testis, Ovary, and Adrenal Gland. Endocrinology, 2002, 143, 4096-4103.	1.4	8
64	Ovulatory Surges of Human CG Prevent Hormone-Induced Granulosa Cell Tumor Formation Leading to the Identification of Tumor-Associated Changes in the Transcriptome. Molecular Endocrinology, 2002, 16, 1230-1242.	3.7	30
65	Ovarian Hyperstimulation by LH Leads to Mammary Cland Hyperplasia and Cancer Predisposition in Transgenic Mice. Endocrinology, 2002, 143, 3671-3680.	1.4	29
66	Minireview: Genetic Models for the Study of Gonadotropin Actions. Endocrinology, 2002, 143, 2823-2835.	1.4	76
67	Monogenic Disorders of Puberty. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2481-2494.	1.8	58
68	Reproductive Disturbances, Pituitary Lactotrope Adenomas, and Mammary Gland Tumors in Transgenic Female Mice Producing High Levels of Human Chorionic Gonadotropin. Endocrinology, 2002, 143, 4084-4095.	1.4	109
69	Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Human Reproduction, 2002, 17, 1171-1180.	0.4	130
70	Transgenic and knockout mouse models for the study of luteinizing hormone and luteinizing hormone receptor function. Molecular and Cellular Endocrinology, 2002, 187, 49-56.	1.6	37
71	Ovarian steroid receptors and their role in ovarian function. Molecular and Cellular Endocrinology, 2002, 191, 27-33.	1.6	75
72	Molecular pathogenesis of granulosa cell tumours. Molecular and Cellular Endocrinology, 2002, 191, 89-96.	1.6	39
73	Inhibins/activins as diagnostic markers for ovarian cancer. Molecular and Cellular Endocrinology, 2002, 191, 97-103.	1.6	57

#	Article	IF	CITATIONS
74	Functional characterization of a natural variant of luteinizing hormone. Human Genetics, 2002, 111, 219-224.	1.8	10
75	The ovarian gonadotropin receptors in health and disease. Reviews in Endocrine and Metabolic Disorders, 2002, 3, 55-63.	2.6	6
76	Estrogen receptors: structure, mechanisms and function. Reviews in Endocrine and Metabolic Disorders, 2002, 3, 193-200.	2.6	118
77	Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. Molecular Reproduction and Development, 2002, 61, 549-559.	1.0	237
78	Methoxychlor-Induced Alterations in the Histological Expression of Angiogenic Factors in Pituitary and Uterus. Journal of Molecular Histology, 2003, 35, 363-375.	1.0	9
79	Targeted ablation of gonadotrophs in transgenic mice depresses prolactin but not growth hormone gene expression at birth as measured by quantitative mRNA detection. Journal of Biomedical Science, 2003, 10, 805-812.	2.6	10
80	Rodent models for ovarian cancer research. International Journal of Gynecological Cancer, 2003, 13, 405-412.	1.2	45
81	High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-α-subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene, 2003, 22, 3269-3278.	2.6	39
82	Oestrogen receptor knockout mice: roles for oestrogen receptors alpha and beta in reproductive tissues. Reproduction, 2003, 125, 143-149.	1.1	218
83	Estrogen receptor knockout mice: phenotypes in the female reproductive tract. Gynecological Endocrinology, 2003, 17, 169-176.	0.7	52
84	Gonadotropins and inhibins along the development of a luteinized rat ovarian tumor. Molecular and Cellular Endocrinology, 2003, 203, 137-146.	1.6	1
85	Update on animal models developed for analyses of estrogen receptor biological activity. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 387-391.	1.2	84
86	Age-related uterine and ovarian hypertrophy in FSH receptor knockout and FSHbeta subunit knockout mice. Reproduction, 2003, 125, 165-173.	1.1	49
87	Characterization of the Hypothalamic-Pituitary-Gonadal Axis in Estrogen Receptor (ER) Null Mice Reveals Hypergonadism and Endocrine Sex Reversal in Females Lacking ERα But Not ERβ. Molecular Endocrinology, 2003, 17, 1039-1053.	3.7	286
88	Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Human Molecular Genetics, 2003, 12, 2063-2076.	1.4	147
89	Overexpression of Human Chorionic Gonadotropin Causes Multiple Reproductive Defects in Transgenic Mice1. Biology of Reproduction, 2003, 69, 338-346.	1.2	83
90	Identification of post-translational modifications resulting from LHbeta polymorphisms by matrix-assisted laser desorption time-of-flight mass spectrometric analysis of pituitary LHbeta core fragment. Journal of Molecular Endocrinology, 2003, 30, 239-252.	1.1	10
91	Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice. Molecular and Cellular Biology, 2003, 23, 3951-3964.	1.1	72

#	Article	IF	CITATIONS
92	Targeted Overexpression of Luteinizing Hormone Causes Ovary-Dependent Functional Adenomas Restricted to Cells of the Pit-1 Lineage. Endocrinology, 2003, 144, 4626-4636.	1.4	22
93	Hypothalamic-Pituitary-Ovarian Axis during Infancy, Early and Late Prepuberty in an Aromatase-Deficient Girl Who Is a Compound Heterocygote for Two New Point Mutations of the CYP19 Gene. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5127-5131.	1.8	86
94	Expression Profiling Analyses of Gonadotropin Responses and Tumor Development in the Absence of Inhibins. Endocrinology, 2003, 144, 4492-4507.	1.4	39
95	Elevated Steroidogenesis, Defective Reproductive Organs, and Infertility in Transgenic Male Mice Overexpressing Human Chorionic Gonadotropin. Endocrinology, 2003, 144, 4980-4990.	1.4	75
96	Sexually Dimorphic Roles of Steroid Hormone Receptor Signaling in Gonadal Tumorigenesis. Molecular Endocrinology, 2003, 17, 2039-2052.	3.7	26
97	Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E812-E818.	1.8	23
98	From the germinal cells to the newborn animal: The transmission of genes and life through the generations. Acta Veterinaria Hungarica, 2003, 51, 371-384.	0.2	0
99	Reexpression of p8 Contributes to Tumorigenic Properties of Pituitary Cells and Appears in a Subset of Prolactinomas in Transgenic Mice that Hypersecrete Luteinizing Hormone. Molecular Endocrinology, 2004, 18, 2583-2593.	3.7	46
100	Comparative Genomic Analysis of the Eight-Membered Ring Cystine Knot-Containing Bone Morphogenetic Protein Antagonists. Molecular Endocrinology, 2004, 18, 1-12.	3.7	208
101	Adrenocortical Tumorigenesis in Transgenic Mice Expressing the Inhibin α-Subunit Promoter/Simian Virus 40 T-Antigen Transgene: Relationship between Ectopic Expression of Luteinizing Hormone Receptor and Transcription Factor GATA-4. Molecular Endocrinology, 2004, 18, 2553-2569.	3.7	45
102	Formation of Cystic Ovarian Follicles Associated with Elevated Luteinizing Hormone Requires Estrogen Receptor-Î ² . Endocrinology, 2004, 145, 4693-4702.	1.4	53
103	Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation. Molecular Endocrinology, 2004, 18, 2570-2582.	3.7	128
104	Multiple and Overlapping Combinatorial Codes Orchestrate Hormonal Responsiveness and Dictate Cell-Specific Expression of the Genes Encoding Luteinizing Hormone. Endocrine Reviews, 2004, 25, 521-542.	8.9	100
105	Role of the Inhibin/Activin System and Luteinizing Hormone in Adrenocortical Tumorigenesis. Hormone and Metabolic Research, 2004, 36, 392-396.	0.7	21
106	Gonadotropin-Releasing Hormone Regulates Expression of the DNA Damage Repair Gene, Fanconi anemia A, in Pituitary Gonadotroph Cells1. Biology of Reproduction, 2004, 71, 828-836.	1.2	14
107	Luteinizing Hormone Receptor-Mediated Effects on Initiation of Spermatogenesis in Gonadotropin-Deficient (hpg) Mice Are Replicated by Testosterone1. Biology of Reproduction, 2004, 70, 32-38.	1.2	61
108	Mechanisms of Hormone-Mediated Carcinogenesis of the Ovary. Toxicologic Pathology, 2004, 32, 1-5.	0.9	19
109	Inhibin/activin and ovarian cancer Endocrine-Related Cancer, 2004, 11, 35-49.	1.6	59

#	Article	IF	CITATIONS
110	Altered Kinetics of Pituitary Response to Gonadotropin-Releasing Hormone in Women with Variant Luteinizing Hormone: Correlation with Ovulatory Disorders. Hormone Research in Paediatrics, 2004, 61, 27-32.	0.8	4
111	The Effects of Estrogen on the Expression of Genes Underlying the Differentiation of Somatic Cells in the Murine Gonad. Endocrinology, 2004, 145, 3950-3960.	1.4	56
112	Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 775-780.	3.3	319
113	Perspectives on reproductive senescence and biological aging: studies in genetically altered follitropin receptor knockout [FORKO] mice. Experimental Gerontology, 2004, 39, 1669-1678.	1.2	17
114	Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Archives of Medical Research, 2004, 35, 103-108.	1.5	300
115	Interspecies Dose Extrapolation for Inhaled Dimethyl Sulfate: A PBPK Model-Based Analysis using Nasal Cavity N7-Methylguanine Adducts. Inhalation Toxicology, 2004, 16, 593-605.	0.8	12
116	Transgenic Models in Pharmacology. Handbook of Experimental Pharmacology, 2004, , .	0.9	3
117	Estrogen and folliculogenesis: is one necessary for the other?. Current Opinion in Obstetrics and Gynecology, 2005, 17, 249-253.	0.9	31
118	Molecular and Histological Studies of Pituitary Tumorigenesis Using Experimental Animal Models. Acta Histochemica Et Cytochemica, 2005, 38, 87-92.	0.8	2
119	Effects of phytoestrogens on the ovarian and pituitary phenotypes of estrogen-deficient female aromatase knockout mice. Menopause, 2005, 12, 174-185.	0.8	24
120	Targeting Gonadotropin Receptor Genes: Reproductive Biology, Aging, and Related Health Implications. Endocrine, 2005, 26, 219-226.	2.2	9
121	Transgenic Models for Exploring Gonadotropin Biology in the Male. Endocrine, 2005, 26, 235-240.	2.2	7
122	The Serotonin Type 3 _A Receptor Facilitates Luteinizing Hormone Release and LHβ Promoter Activity in Immortalized Pituitary Gonadotropes. Endocrine, 2005, 27, 037-044.	2.2	7
123	Recent Progress in Studies of Pituitary Tumor Pathogenesis. Endocrine, 2005, 28, 037-042.	2.2	15
124	A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. International Journal of Gynecological Cancer, 2005, 15, 246-254.	1.2	5
126	Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research, 2005, 322, 117-124.	1.5	55
127	What makes a good egg?. , 2005, , 103-118.		0
128	Ectopic Bioactive Luteinizing Hormone Secretion by a Pancreatic Endocrine Tumor, Manifested as Luteinized Granulosa-Thecal Cell Tumor of the Ovaries. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2097-2103.	1.8	25

#	Article	IF	CITATIONS
129	The LHÎ ² Gene of Several Mammals Embeds a Carboxyl-terminal Peptide-like Sequence Revealing a Critical Role for Mucin Oligosaccharides in the Evolution of Lutropin to Chorionic Gonadotropin in the Animal Phyla. Journal of Biological Chemistry, 2005, 280, 16676-16684.	1.6	17
130	Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin–lutropin receptor complex. Journal of Molecular Endocrinology, 2005, 34, 489-503.	1.1	33
131	Decreased Gonadotropin-Releasing Hormone Neuronal Activity Is Associated with Decreased Fertility and Dysregulation of Food Intake in the Female GPR-4 Transgenic Rat. Endocrinology, 2005, 146, 3800-3808.	1.4	3
132	What have gonadotrophin overexpressing transgenic mice taught us about gonadal function?. Reproduction, 2005, 130, 283-291.	1.1	32
133	No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Human Reproduction, 2005, 20, 965-969.	0.4	31
134	Targeted overexpression of calcitonin in gonadotrophs of transgenic mice leads to chronic hypoprolactinemia. Molecular and Cellular Endocrinology, 2005, 229, 193-203.	1.6	14
135	Multiple sites of tumorigenesis in transgenic mice overproducing hCG. Molecular and Cellular Endocrinology, 2005, 234, 117-126.	1.6	35
136	EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Letters, 2005, 229, 205-215.	3.2	24
137	Mouse genetic models for aneuploidy induction in germ cells. Cytogenetic and Genome Research, 2005, 111, 392-400.	0.6	13
138	LESSONS IN ESTROGEN BIOLOGY FROM KNOCKOUT AND TRANSGENIC ANIMALS. Annual Review of Physiology, 2005, 67, 285-308.	5.6	262
139	Differential Expression of Claudin Family Proteins in Mouse Ovarian Serous Papillary Epithelial Adenoma in Aging FSH Receptor-Deficient Mutants. Neoplasia, 2006, 8, 984-994.	2.3	20
140	Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. Journal of Endocrinology, 2006, 189, 199-209.	1.2	173
141	Genetically modified mouse models in studies of luteinising hormone action. Molecular and Cellular Endocrinology, 2006, 252, 126-135.	1.6	35
142	Mutations along the pituitary–gonadal axis affecting sexual maturation: Novel information from transgenic and knockout mice. Molecular and Cellular Endocrinology, 2006, 254-255, 84-90.	1.6	57
143	Estrogen receptors and human disease. Journal of Clinical Investigation, 2006, 116, 561-570.	3.9	1,077
144	Developing Animal Models for Analyzing SERM Activity. Annals of the New York Academy of Sciences, 2001, 949, 36-43.	1.8	7
145	Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene, 2006, 25, 3325-3334.	2.6	25
146	Homologous and Heterologous Carboxyl Terminal Peptide (CTP) Linker Sequences Enhance the Secretion of Bioactive Single-Chain Bovine LH Analogs. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 95-104.	0.6	12

# 147	ARTICLE The Intraovarian Actions of Estrogen Receptor-α Are Necessary to Repress the Formation of Morphological and Functional Leydig-Like Cells in the Female Gonad. Endocrinology, 2006, 147, 3666-3678.	IF 1.4	CITATIONS
148	Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). PPAR Research, 2006, 2006, 1-8.	1.1	38
149	Follicular DevelopmentMouse, Sheep, and Human Models. , 2006, , 383-423.		16
150	Ovarian follicle development and transgenic mouse models. Human Reproduction Update, 2006, 12, 537-555.	5.2	103
151	Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-8.	3.0	13
152	Steroid Receptors in the Ovary and Uterus. , 2006, , 593-678.		14
153	Single-Chain Bifunctional Vascular Endothelial Growth Factor (VEGF)-Follicle-Stimulating Hormone (FSH)-C-Terminal Peptide (CTP) Is Superior to the Combination Therapy of Recombinant VEGF plus FSH-CTP in Stimulating Angiogenesis during Ovarian Folliculogenesis. Endocrinology, 2007, 148, 1296-1305.	1.4	8
154	The Pleiotropic Effects of Excessive Luteinizing Hormone Secretion in Transgenic Mice. Seminars in Reproductive Medicine, 2007, 25, 360-367.	0.5	Ο
155	Lutropin/Choriogonadotropin Stimulate the Proliferation of Primary Cultures of Rat Leydig Cells through a Pathway that Involves Activation of the Extracellularly Regulated Kinase 1/2 Cascade. Endocrinology, 2007, 148, 3214-3225.	1.4	97
156	Genetic Removal of Smad3 from Inhibin-Null Mice Attenuates Tumor Progression by Uncoupling Extracellular Mitogenic Signals from the Cell Cycle Machinery. Molecular Endocrinology, 2007, 21, 2440-2457.	3.7	54
157	Female Genital Tract. , 2007, , 717-779.		1
158	LH analog and dietary isoflavones support ovarian granulosa cell tumor development in a spontaneous mouse model. Endocrine-Related Cancer, 2007, 14, 369-379.	1.6	15
159	Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. Journal of Molecular Endocrinology, 2007, 39, 9-16.	1.1	35
160	Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor–pituitary tumor transforming gene transgenic mice. Journal of Endocrinology, 2007, 194, 179-191.	1.2	13
161	Potential Leydig cell mitogenic signals generated by the wild-type and constitutively active mutants of the lutropin/choriogonadotropin receptor (LHR). Molecular and Cellular Endocrinology, 2007, 260-262, 244-248.	1.6	22
162	Phenotypic characterisation of mice with exaggerated and missing LH/hCG action. Molecular and Cellular Endocrinology, 2007, 260-262, 255-263.	1.6	17
163	Strategies for construction of luteinizing hormone beta subunit analogs with carboxyl terminal extensions in non-primate, non-equid mammalian species. Molecular and Cellular Endocrinology, 2007, 260-262, 205-211.	1.6	4
164	Constitutively active luteinizing hormone receptors: Consequences of in vivo expression. Molecular and Cellular Endocrinology, 2007, 260-262, 294-300.	1.6	23

#	Article	IF	CITATIONS
165	Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology, 2007, 269, 107-111.	1.6	103
166	Mouse models for gonadotropins: A 15-year Saga. Molecular and Cellular Endocrinology, 2007, 260-262, 249-254.	1.6	24
167	Extragonadal LH/hCG action—Not yet time to rewrite textbooks. Molecular and Cellular Endocrinology, 2007, 269, 9-16.	1.6	50
168	Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6. Molecular and Cellular Endocrinology, 2007, 269, 38-45.	1.6	35
170	Gonadotropins and Ovarian Cancer. Endocrine Reviews, 2007, 28, 440-461.	8.9	120
171	Rat Models of Polycystic Ovary Syndrome. , 2008, , 405-410.		3
172	Luteinizing hormone promotes gonadal tumorigenesis in inhibin-deficient mice. Molecular and Cellular Endocrinology, 2008, 294, 19-28.	1.6	19
173	Conditional Deletion of <i>Smad1</i> and <i>Smad5</i> in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice. Molecular and Cellular Biology, 2008, 28, 248-257.	1.1	189
174	Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin conjugate. Endocrine-Related Cancer, 2008, 15, 635-648.	1.6	12
176	An Estrogen Receptor-α Knock-In Mutation Provides Evidence of Ligand-Independent Signaling and Allows Modulation of Ligand-Induced Pathways in Vivo. Endocrinology, 2008, 149, 2970-2979.	1.4	69
177	Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis, 2008, 29, 2062-2072.	1.3	78
178	Ovarian Histological Findings in an Adult Patient with the Steroidogenic Acute Regulatory Protein (StAR) Deficiency Reveal the Impairment of Steroidogenesis by Lipoid Deposition. Endocrine Journal, 2008, 55, 1043-1049.	0.7	23
179	Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Nonâ€Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ: Applications in Evaluating Novel Therapeutic Agents. Current Protocols in Pharmacology, 2009, 45, Unit14.12.	4.0	36
180	Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence. Hormone Research in Paediatrics, 2009, 72, 321-330.	0.8	92
181	Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research. Molecular Human Reproduction, 2009, 15, 703-711.	1.3	42
182	The Mammalian Ovary from Genesis to Revelation. Endocrine Reviews, 2009, 30, 624-712.	8.9	630
183	Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor \hat{I}_{\pm} knock-in (ENERKI) mice. Steroids, 2009, 74, 913-919.	0.8	8
184	Increases in norepinephrine release and ovarian cyst formation during ageing in the rat. Reproductive Biology and Endocrinology, 2009, 7, 64.	1.4	32

#	Article	IF	CITATIONS
185	Luteinizing Hormone Receptor Deficiency Increases the Susceptibility to Alkylating Agent-Induced Lymphomagenesis in Mice. Hormones and Cancer, 2010, 1, 256-264.	4.9	1
186	Development of a syngeneic mouse model of epithelial ovarian cancer. Journal of Ovarian Research, 2010, 3, 24.	1.3	45
187	Alternative Mouse Models for Carcinogenicity Assessment: Industry Use and Issues with Pathology Interpretation. Toxicologic Pathology, 2010, 38, 43-50.	0.9	31
188	Inhibin-A Antagonizes TCFβ2 Signaling by Down-Regulating Cell Surface Expression of the TCFβ Coreceptor Betaglycan. Molecular Endocrinology, 2010, 24, 608-620.	3.7	36
189	Minireview: Physiological and Pathological Actions of RAS in the Ovary. Molecular Endocrinology, 2010, 24, 286-298.	3.7	43
190	Ovarian Cancer and the Environment: Rodent Models*. , 2010, , 483-498.		1
191	The lack of estrogen and excess luteinizing hormone are responsible for the female ArKO mouse phenotypeâ~†. Molecular and Cellular Endocrinology, 2010, 327, 56-64.	1.6	16
192	Luteinizing hormone β-subunit gene (LHβ) polymorphism in infertility and endometriosis-associated infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 151, 66-69.	0.5	23
193	Alterations of the pituitary-ovarian axis in dogs with a functional granulosa cell tumor.	0.9	17
	menogenology, 2010, 73, 11 13.		
194	Ovarian Toxicology. , 2010, , 381-398.		0
194 196	Ovarian Toxicology., 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557.	0.8	9
194 196 197	Ovarian Toxicology. , 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCG Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCG/LH and ERBB-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630.	0.8	0 9 13
194 196 197 198	Ovarian Toxicology. , 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCG Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCG/LH and ERBB-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630. Animal models for aberrations of gonadotropin action. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 245-258.	0.8 1.0 2.6	0 9 13 10
194 196 197 198	Ovarian Toxicology. , 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCC Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCC/LH and ERBB-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630. Animal models for aberrations of gonadotropin action. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 245-258. Genetic aspects of premature ovarian failure: a literature review. Archives of Gynecology and Obstetrics, 2011, 283, 635-643.	0.8 1.0 2.6 0.8	0 9 13 10 145
 194 196 197 198 199 200 	Ovarian Toxicology. , 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCG Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCC/LH and ERBB-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630. Animal models for aberrations of gonadotropin action. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 245-258. Genetic aspects of premature ovarian failure: a literature review. Archives of Gynecology and Obstetrics, 2011, 283, 635-643. Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility. Endocrinology, 2012, 153, 5980-5992.	0.8 1.0 2.6 0.8 1.4	0 9 13 10 145 17
 194 196 197 198 199 200 201 	Ovarian Toxicology, 2010, 7, 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCG Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCG/LH and ERBE-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630. Animal models for aberrations of gonadotropin action. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 245-258. Genetic aspects of premature ovarian failure: a literature review. Archives of Gynecology and Obstetrics, 2011, 283, 635-643. Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility. Endocrinology, 2012, 153, 5980-5992. Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. Endocrine Reviews, 2012, 33, 109-144.	0.8 1.0 2.6 0.8 1.4	0 9 13 10 145 17 164
 194 196 197 198 199 200 201 202 	Ovarian Toxicology. , 2010, , 381-398. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause, 2011, 18, 549-557. HCG Hastens Both the Development of Mammary Carcinoma and the Metastatization of HCG/LH and ERBB-2 Receptor-Positive Cells in Mice. International Journal of Immunopathology and Pharmacology, 2011, 24, 621-630. Animal models for aberrations of gonadotropin action. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 245-258. Genetic aspects of premature ovarian failure: a literature review. Archives of Gynecology and Obstetrics, 2011, 283, 635-643. Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility. Endocrinology, 2012, 153, 5980-5992. Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. Endocrine Reviews, 2012, 33, 109-144. Rodent Models for Human Polycystic Ovary Syndrome1. Biology of Reproduction, 2012, 86, 149, 1-12.	0.8 1.0 2.6 0.8 1.4 8.9	0 9 13 10 145 17 164 227

#	Article	IF	CITATIONS
204	Transgenesis-Mediated Reproductive Dysfunction and Tumorigenesis: Effects of Immunological Neutralization. PLoS ONE, 2012, 7, e51125.	1.1	9
205	The Consequences of Mutations in the Reproductive Endocrine System. Development & Reproduction, 2012, 16, 235-251.	0.5	3
206	<i>Fancf</i> â€deficient mice are prone to develop ovarian tumours. Journal of Pathology, 2012, 226, 28-39.	2.1	31
207	Dysregulation of Ovarian Follicular Development in Female Rat: LH Decreases FSH Sensitivity During Preantral-Early Antral Transition. Endocrinology, 2013, 154, 2870-2880.	1.4	35
208	Acupuncture in Polycystic Ovary Syndrome: Potential and Challenge. , 2013, , 487-515.		1
209	Gonadotropin-Releasing Hormone-Regulated Prohibitin Mediates Apoptosis of the Gonadotrope Cells. Molecular Endocrinology, 2013, 27, 1856-1870.	3.7	26
210	Transgenic GATA-4 expression induces adrenocortical tumorigenesis in C57Bl/6 mice. Journal of Cell Science, 2013, 126, 1845-57.	1.2	36
211	Long-term clinical data and molecular defects in the STAR gene in five Greek patients. European Journal of Endocrinology, 2013, 168, 351-359.	1.9	6
212	Childhood Obesity and Its Impact on the Development of Adolescent PCOS. Seminars in Reproductive Medicine, 2014, 32, 202-213.	0.5	103
213	FOXL2: a central transcription factor of the ovary. Journal of Molecular Endocrinology, 2014, 52, R17-R33.	1.1	125
214	Mouse models of altered gonadotrophin action: insight into male reproductive disorders. Reproduction, 2014, 148, R63-R70.	1.1	21
215	Mouse models to study polycystic ovary syndrome: A possible link between metabolism and ovarian function?. Reproductive Biology, 2014, 14, 32-43.	0.9	82
216	Genetically modified mouse models addressing gonadotropin function. Reproductive Biology, 2014, 14, 9-15.	0.9	5
217	Neoplastic and Nonneoplastic Lesions in Aging Mice of Unique and Common Inbred Strains Contribution to Modeling of Human Neoplastic Diseases. Veterinary Pathology, 2014, 51, 663-679.	0.8	30
218	Constitutive Activity in Gonadotropin Receptors. Advances in Pharmacology, 2014, 70, 37-80.	1.2	29
219	The role of the 3′ region of mammalian gonadotropin β subunit gene in the luteinizing hormone to chorionic gonadotropin evolution. Molecular and Cellular Endocrinology, 2014, 382, 781-790.	1.6	7
220	Genetic Models for the Study of Luteinizing Hormone Receptor Function. Frontiers in Endocrinology, 2015, 6, 152.	1.5	40
221	Insulin Receptor Signaling in the GnRH Neuron Plays a Role in the Abnormal GnRH Pulsatility of Obese Female Mice. PLoS ONE, 2015, 10, e0119995.	1.1	54

#	Article	IF	CITATIONS
222	Infertility in Female Mice with a Gain-of-Function Mutation in the Luteinizing Hormone Receptor Is Due to Irregular Estrous Cyclicity, Anovulation, Hormonal Alterations, and Polycystic Ovaries1. Biology of Reproduction, 2015, 93, 16.	1.2	19
223	The recombinant equine LHβ subunit combines divergent intracellular traits of human LHβ and CGβ subunits. Theriogenology, 2015, 83, 1469-1476.	0.9	3
224	The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocrine-Related Cancer, 2015, 22, R339-R363.	1.6	33
225	Steroid Receptors in the Uterus and Ovary. , 2015, , 1099-1193.		11
226	Follicular Development. , 2015, , 947-995.		12
227	Hormone Signaling in the Testis. , 2015, , 637-690.		30
228	Insights into granulosa cell tumors using spontaneous or genetically engineered mouse models. Clinical and Experimental Reproductive Medicine, 2016, 43, 1.	0.5	7
229	Mouse Models for the Study of Synthesis, Secretion, and Action of Pituitary Gonadotropins. Progress in Molecular Biology and Translational Science, 2016, 143, 49-84.	0.9	10
230	Perspectives in Polycystic Ovary Syndrome: From Hair to Eternity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 759-768.	1.8	71
231	Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells inÂvitro. Molecular and Cellular Endocrinology, 2016, 422, 103-114.	1.6	70
232	Mouse models of adrenocortical tumors. Molecular and Cellular Endocrinology, 2016, 421, 82-97.	1.6	13
233	Novel genes involved in pathophysiology of gonadotropin-dependent adrenal tumors in mice. Molecular and Cellular Endocrinology, 2017, 444, 9-18.	1.6	5
234	Reproductive disorders in female rats after prenatal exposure to betamethasone. Journal of Applied Toxicology, 2017, 37, 1065-1072.	1.4	16
235	The role of Notch signaling in the mammalian ovary. Reproduction, 2017, 153, R187-R204.	1.1	69
236	The acceleration of reproductive aging in <i>Nrg1</i> ^{<i>flox/flox</i>} <i>;Cyp19 re</i> female mice. Aging Cell, 2017, 16, 1288-1299.	3.0	28
237	Gonadotropin Receptors. Endocrinology, 2017, , 123-168.	0.1	5
238	Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro. Reproductive Biology and Endocrinology, 2017, 15, 2.	1.4	77
239	Mouse models for the analysis of gonadotropin secretion and action. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 219-239.	2.2	8

#	Article	IF	CITATIONS
240	FSHR Trans-Activation and Oligomerization. Frontiers in Endocrinology, 2018, 9, 760.	1.5	16
241	Ovarian Cancer and the Environment: Rodent Models. , 2018, , 362-380.		1
242	Ovarian Toxicology. , 2018, , 341-361.		0
243	Crocetin attenuates DHT-induced polycystic ovary syndrome in mice via revising kisspeptin neurons. Biomedicine and Pharmacotherapy, 2018, 107, 1363-1369.	2.5	29
244	Ovarian and extra-ovarian mediators in the development of polycystic ovary syndrome. Journal of Molecular Endocrinology, 2018, 61, R161-R184.	1.1	26
245	Androgen exposure potentiates formation of intratubular communities and renal abscesses byÂEscherichia coli. Kidney International, 2018, 94, 502-513.	2.6	23
246	Experimental models of polycystic ovary syndrome: An update. Life Sciences, 2019, 237, 116911.	2.0	15
247	Animal Models for Human Polycystic Ovary Syndrome (PCOS) Focused on the Use of Indirect Hormonal Perturbations: A Review of the Literature. International Journal of Molecular Sciences, 2019, 20, 2720.	1.8	43
248	Dysregulation of hypothalamicâ€pituitary estrogen receptor α–mediated signaling causes episodic LH secretion and cystic ovary. FASEB Journal, 2019, 33, 7375-7386.	0.2	18
249	Hyperandrogenic origins of polycystic ovary syndrome – implications for pathophysiology and therapy. Expert Review of Endocrinology and Metabolism, 2019, 14, 131-143.	1.2	87
251	Embryo Selection and Mate Choice: Can â€~Honest Signals' Be Trusted?. Trends in Ecology and Evolution, 2020, 35, 308-318.	4.2	17
252	Associations of exposure to phthalates and environmental phenols with gynecological disorders. Reproductive Toxicology, 2020, 95, 19-28.	1.3	19
253	Direct impact of gonadotropins on glucose uptake and storage in preovulatory granulosa cells: Implications in the pathogenesis of polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2021, 115, 154458.	1.5	12
254	Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. Life Sciences, 2021, 280, 119753.	2.0	33
255	Association between gene expression levels of GDF9 and BMP15 and clinicopathological factors in the prognosis of female infertility in northeast Indian populations. Meta Gene, 2021, 30, 100964.	0.3	0
257	Animal Models of Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 353-391.	0.2	15
258	Insights Into Leydig Cell Function From Mice With Genetically Modified Gonadotropin Action. , 2007, , 253-261.		1
259	Gonadotrophin Receptors. Endocrinology, 2016, , 1-46.	0.1	1

#	Article	IF	CITATIONS
260	GonadotropinsChemistry and Biosynthesis. , 2006, , 1581-1634.		14
261	Manipulating the In Vivo mRNA Expression Profile of FSHbeta to Resemble that of LHbeta Does Not Promote a Concomitant Increase in Intracellular Storage of Follicle-Stimulating Hormone. Journal of Neuroendocrinology, 2001, 13, 50-62.	1.2	10
262	Effects of propylene glycol or elevated luteinizing hormone during follicle development on ovulation, fertilization, and early embryo developmentâ€. Biology of Reproduction, 2017, 97, 550-563.	1.2	4
263	Clearing the way to implantation. Journal of Clinical Investigation, 2002, 109, 169-170.	3.9	1
264	Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. Journal of Clinical Investigation, 2000, 105, 633-641.	3.9	140
265	Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development (Cambridge), 2000, 127, 4277-4291.	1.2	906
266	Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection. Topics in Spinal Cord Injury Rehabilitation, 2019, 25, 228-240.	0.8	88
267	GnRH antagonist treatment of malignant adrenocortical tumors. Endocrine-Related Cancer, 2019, 26, 103-117.	1.6	14
268	The stromal fibrosis in aging ovary. Aging, 2018, 10, 9-10.	1.4	20
269	The gonadotropin system, lessons from animal models and clinical cases. Minerva Ginecologica, 2018, 70, 561-587.	0.8	10
272	La physiologie ovarienne : ce que nous disent les souris Medecine/Sciences, 1999, 15, 141.	0.0	2
273	Transgenic Approaches to Study Developmental Expression and Regulation of the Gonadotropin Genes. , 2000, , 217-237.		0
275	Control of Ovarian Function. , 2001, , 61-89.		4
276	LH Hypersecreting Mice: A Model for Ovarian Granulosa Cell Tumors. Growth Hormone, 2001, , 59-78.	0.2	0
277	Reproductive System. Handbook of Experimental Pharmacology, 2004, , 607-635.	0.9	0
278	Gonadotrophin receptors. , 2004, , 22-43.		0
279	Ablation of GalNAc-4-sulfotransferase-1 enhances reproduction by altering the carbohydrate structures of luteinizing hormone in mice. Journal of Clinical Investigation, 2008, 118, 1815-24.	3.9	22
280	Steroid Hormones and Ovarian Cancer. , 0, , .		0

#	Article	IF	CITATIONS
281	Physiological Findings from Transgenic Mouse Models with Altered Levels of Estrogen Receptor Expression. , 1997, , 69-98.		2
283	Activation of Ovarian Cortex. , 2020, , 315-327.		0
284	Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Current Protocols in Pharmacology, 2009, 45, 14.12.1-14.12.26.	4.0	15
285	Differential response to sustained stimulation by hCG & LH on goat ovarian granulosa cells. Indian Journal of Medical Research, 2012, 135, 331-40.	0.4	13
286	Genetic modeling of ovarian phenotypes in mice for the study of human polycystic ovary syndrome. American Journal of Translational Research (discontinued), 2013, 5, 15-20.	0.0	2
287	Evidence-based hormonal, mutational, and endocrine-disrupting chemical-induced zebrafish as an alternative model to study PCOS condition similar to mammalian PCOS model. Life Sciences, 2022, 291, 120276.	2.0	18
289	Estrogen alpha receptor inactivation in two sisters: different phenotypic severities for the same pathogenic variant. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	3
294	Targeted ablation of gonadotrophs in transgenic mice depresses prolactin but not growth hormone gene expression at birth as measured by quantitative mRNA detection. Journal of Biomedical Science, 2003, 10, 805-12.	2.6	6
295	The requirement of ubiquitin C-terminal hydrolase L1 in mouse ovarian development and fertility. Biology of Reproduction, 2022, 107, 500-513.	1.2	6